Repros announces results of its Androxal efficacy study for secondary hypogonadism

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal^®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary. The study was designed to compare Androxal to Testim^®1% (Auxilium Pharmaceuticals Inc, Malvern, PA), an approved topical testosterone gel, indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Transdermal testosterone use has been associated with suppression of pituitary gonadotrophic hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH), both necessary for stimulating testosterone production and spermatogenesis in the testes. Androxal is an oral therapy intended to restore normal brain-pituitary-testes interaction and thus testicular function in men with secondary hypogonadism.